This week, the US health-research landscape is disrupted by the Trump administration's sudden halt of National Institutes of Health grant reviews, halting 80% of its $47 billion budget for research. Meanwhile, DeepSeek-R1, a new Chinese-built language model, has emerged as a cost-effective competitor to established AI models, providing open-weight access for further study. Additionally, 23andMe, a pioneer in the genetic-testing market, faces uncertainty as its once-booming business model falters amidst limited partnerships and reliance on one-time product sales, signaling vulnerabilities in the industry.
The US health-research community faces turmoil as the Trump administration cancels NIH grant reviews and freezes 80% of its $47 billion budget, impacting research significantly.
The Chinese-built DeepSeek-R1 model emerges as a competitive alternative to established models like OpenAI's, noted for its 'open-weight' status allowing further research and exploration.
23andMe's decline underscores the vulnerability of the genetic-testing industry, as the company's one-time products and limited pharmaceutical collaborations have led to a crisis in its future.
Researchers express concerns over the unprecedented length of the research funding freeze, calling it a significant disruption that could have long-term impacts on scientific progress.
Collection
[
|
...
]